期刊文献+

内皮素在大鼠烧伤早期心脏损害中作用的研究 被引量:1

Role of endogenous endothelins in heart injury in burnt rats
下载PDF
导出
摘要 本研究应用30%Ⅲ度烧伤大鼠模型,旨在探讨烧伤早期内皮素变化规律及其在心脏损害中的作用,通过对大鼠烧伤后血浆、心脏内皮素含量动态变化及非选择性内皮素受体拮抗剂PD145065对心脏损害防治作用的观察。研究发现:烧伤后血浆及心肌组织内皮素明显增加,且与伤后心脏含水量的改变有一定的相关性;伤后及时应用PD145065则可一定程度增加心肌组织SOD、Na+-K+-ATP酶活性及ATP、ADP含量,减少MDA、AMP含量,减轻组织水肿,光、电镜检查也证实可减轻心脏损害。这些结果表明烧伤后内源性内皮素的增加参与了烧伤早期心脏损害的发生,其机制可能是伤后异常升高的内皮素通过收缩血管造成心肌组织缺血缺氧性损害,继而导致能量代谢紊乱及脂质过氧化损害。 The purpose of this study was to investigate the role of endogenous endothelins in postburn heart injury by use of a 30% TBSA Ⅲ degree burnt rat model. Dynamic changes of endothelins in postburn rats were measured, and the effects of PD 145065 , a kind of non selective endothelin receptor antagonist, on heart injury in burnt rats were observed. The main results were as follows: Not only did the endothelin concentration in plasma of burnt rats elevate significantly, but also the endothelin contents in heart muscle apparently increased, which negatively correlated with the changes of water content in heart. Administration of endothelin receptor antagonist PD 145065 had been morphologically and biochemically demonstrated to be able to prevent heart from damage to some extents, by means of stimulation of the activity of SOD or N +-K + ATPase, enhancement of the contents of ATP and ADP, and reduction of the severity of edema in heart. These results suggest that endogenous endothelin may contribute to the postburn heart injury in the early stages in rats through vascular contraction and tissue hypoxia which in turn induces ATP depletion and lipoperoxidation damage.
出处 《军医进修学院学报》 CAS 1997年第3期175-178,共4页 Academic Journal of Pla Postgraduate Medical School
基金 国家自然科学基金
关键词 烧伤 内皮素 心脏 动物实验 burn endothelin heart rats
  • 相关文献

同被引文献39

  • 1卞留贯,孙青芳,田恒力,张天锡.一氧化氮、内皮素-1在兔脑局灶性脑缺血中相互关系[J].上海医科大学学报,1997,24(1):45-47. 被引量:13
  • 2袁文俊 林丽 等.内皮素受体拮抗剂对猫急性缺血性心律失常的影响[J].第二军医大学学报,1997,18:127-127.
  • 3Clozel M,Breu V,GRAY GA,et al.Pharmacological characterization of Bosentan,a new potent orally active nonpeptide endothelin receptor antagonist[J].J Pharmacol Exp The,1994,270:228
  • 4Williams DL,Murphy KL, Nolan NA, et al. Pharmacology of L754, 142, a highly potent orally active, nonpeptide endothelin antagonist[J]. J Pharmacol Exp Ther,1995,275: 1518
  • 5Reynolds EE,Keiser JA,Haleen SJ,et al.Pharmacological characterization of PD156707 an orally active ETA receptor antagonist[J]. J Pharmacol Exp Ther,1995,273:1410
  • 6Elliott J D, Lago MA, Cousins RD,et al. 1,30-Diarylinda-2-Carboxylic Acids, potent and Selective non-peptide endothelin Receptor Antagonists[J]. J Med Chem,1994:37 1553
  • 7Hoshino T,Yamauchi R ,Kikkawa K,et al.Phmarmacologicall profile of T-0201, a highly potent and orally active endothelin receptor antagonist[J]. J Pharmacol Exp Ther ei al,1998,286: 643
  • 8Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1 mediatid vasoconstriction in severe chronic heart failure[J]. Lancet,1995,346(8977):732
  • 9Miyauchi T and Goto K. Heart failare and endothelin receptor antagonists[J]. Jap Rev Physiol,1999,61:391
  • 10Love MP, Haynes WG, Gray GA, et al. Vasodilation effect of endothelin -conventing enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors[J]. Circulation,1996,94: 2131

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部